[Typical Report of the Fifth Anniversary of the Implementation of the Traditional Chinese Medicine Law ②] Kangyuan Pharmaceutical: Playing innovative melody on the research and development main road

Content source: China Traditional Chinese Medicine Reporter: Lin Xiaofei

Since the implementation of the Chinese Medicine Law, Kangyuan Pharmaceutical has paid attention to the use of modern scientific interpretation of the principles of traditional Chinese medicine.

49 new Chinese medicines and new medicines, 21 new Chinese medicines are in the clinical research stage; more than 10%are extracted from sales revenue each year as research and development expenses for scientific and technological innovation; more than 70%of the master's degree and doctoral degree in more than 300 people; 2021 The Chinese Medicine Innovation Pharmaceutical Kangyuan Yinqiao Qinghe tablet approved by the State Drug Administration is the first Chinese medicine innovation drug declared in accordance with type 1.1 innovative drugs since the implementation of the new Chinese medicine registration classification.

In a series of data, "R & D" and "Innovation" are high -frequency words in the development of Kangyuan Pharmaceutical. Article 29 of the Traditional Chinese Medicine Law stipulates: "the state encourages and supports the development and production of new medicines for traditional Chinese medicine. Encourage the use of modern science and technology to research and develop traditions of Chinese medicines."

In the past five years, Kangyuan Pharmaceutical has paid attention to the use of modern scientific interpretation of the principles of traditional Chinese medicine, combining the original thinking of traditional Chinese medicine with modern technology, giving full play to the unique advantages of traditional Chinese medicine, and forming a number of original and leading modern Chinese medicine scientific and technological achievements. Focusing on the advantages of Chinese medicine gynecology, anti -infection, cardiovascular and cerebrovascular, orthopedics, etc., Kangyuan Pharmaceutical Relying on the new technologies of the Chinese medicine and pharmaceutical process of enterprises and the National Joint Engineering Research Center of Sino -Pharmaceutical Intelligent Manufacturing National Joint Engineering Research Center. In the applies, modern drug research and development science and technology have developed an innovative Chinese medicine with clear material foundations, clear mechanisms, and modern medical identity. At present, 49 exclusive Chinese medicines have been developed and listed on the market, and 21 new Chinese medicines have been developed in different stages of clinical research.

In 2021, of the nine traditional Chinese medicine innovation medicine approved by the State Drug Administration, Kangyuan Yinqiao Qing hot tablets were among them. It is the first Chinese medicine innovation drug that has been declared in accordance with type 1.1 innovative drugs since the implementation of the new Chinese medicine registration classification. In the new crown pneumonia's epidemic in 2020, more than 50 million yuan donated by Kangyuan's "Food No. 1 Chinese Medicine Anti -Epidemia" has now applied for new drug registration to the State Drug Administration and has entered the "Special Review Approval Procedure". This is the country. This is the country. The first variety after approving the "three medicines and three parties".

At present, there is a large gap between the current status of Chinese medicine standards and international drug standards. This is mainly because the standards of proprietary Chinese medicines are backward, and there are problems with the problem of less index components and the lack of efficacy. It is difficult to ensure the safety and effectiveness of the medicine. In response to the above problems, Kangyuan Pharmaceuticals has established a prediction of Chinese medicine and efficacy -related components through the scale and rapid separation of preparation technical research on Chinese pads. "The research method has formed a production process quality consistency control system, so as to build a collection of Chinese medicine -related quality control systems that integrate and produce.

经过多年的研发，康缘药业提出并构建了复方中药与功效相关的质量控制体系，实现了以“功效物质群与临床疗效一致性”为质控目标的生产全过程质量控制，显著提高了The quality of proprietary Chinese medicines is uniform, guaranteed effectiveness, and was widely recognized at home and abroad.

Innovation is the motivation of enterprises, and talent is the key to innovation. By continuously improving the construction of the company's talent system, Kangyuan Pharmaceutical has established mechanisms to introduce, cultivate, and use the "main body, intellectual property as the bond, and win -win benefits" to focus on industrial subjects, optimize the talent team, create innovation, and create innovation The chain has gathered a large number of high -level innovative technical talents. Last year, he was approved as an independent post -doctoral post -doctoral workstation with doctoral qualifications. Innovative Chinese medicine R & D team was awarded the "Sixth National Professional and Technical Talent Advanced Collective".

In addition, Kangyuan guided the young scientists of enterprises to follow the original mission of "revitalizing the Chinese medicine to report the motherland". Based on the research concept of "Bosi Jingyi and Pu Yuanzhi", they actively explored and focused on research and development, and continuously improved the research and development platform. Innovative talents of career gathered to innovate.

Typical Report of the Fifth Anniversary of the Implementation of the Traditional Chinese Medicine Law ① Nanjing University of Traditional Chinese Medicine: Make Chinese medicine talents "Chinese" stronger

Edit: Dong Juntong

- END -